The zorbtive or serostim market research report is one of a series of new reports that provides zorbtive or serostim market statistics, including zorbtive or serostim industry global market size, regional shares, competitors with a zorbtive or serostim market share, detailed zorbtive or serostim market segments, market trends and opportunities, and any further data you may need to thrive in the zorbtive or serostim industry. This zorbtive or serostim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to the rise in telemedicine platforms, the rise in demand for personalized and targeted treatments, the growth in research and development efforts, the surge in the aging population, and the increase in the prevalence of growth hormone deficiencies. Major trends in the forecast period include a shift towards precision medicine in hormone therapy, the use of home-based injection devices for patient convenience, the popularity of biosimilars as cost-effective alternatives, advancements in drug delivery technologies, and the expansion of market presence in emerging economies.
The rising number of patients with HIV is expected to drive the growth of the Zorbtive or Serostim market in the future. HIV is a virus that weakens the immune system by targeting CD4 cells, which are crucial for defending the body against infections. The increasing prevalence of HIV can be attributed to factors such as unprotected sexual activity, limited access to preventive healthcare, inadequate awareness and education, and difficulties in HIV testing and treatment, especially in high-risk populations. Zorbtive or Serostim addresses HIV-associated wasting syndrome by promoting weight gain, increasing lean body mass, and improving physical function and quality of life for patients with weakened immune systems due to the virus. For example, in April 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 31,800 new HIV infections occurred in the U.S. in 2022, with a significant portion of these cases among gay, bisexual, and other men who reported male-to-male sexual contact. This rising number of HIV patients is contributing to the growth of the Zorbtive or Serostim market.
The increasing focus on personalized treatments is also expected to fuel the growth of the Zorbtive or Serostim market. Personalized medicine tailors therapy to an individual's genetic, environmental, and lifestyle factors to improve treatment outcomes. Advancements in genetic research, better diagnostic tools, and a growing demand for more effective, targeted therapies are driving the rise in personalized treatments. Zorbtive or Serostim fits into this trend by offering a personalized approach to managing HIV-associated wasting syndrome. It helps promote weight gain, increases lean body mass, and enhances physical function, addressing the specific needs of patients with compromised immune systems due to HIV while improving their quality of life. For instance, the Personalized Medicine Coalition reported in February 2023 that personalized medicines accounted for 34% of new drug approvals by the U.S. FDA in 2022 and have consistently made up at least 25% of approvals over the past eight years. This growing emphasis on personalized medicine is likely to drive the Zorbtive or Serostim market.
The overall increase in healthcare spending and investment is expected to further support the growth of the Zorbtive or Serostim market. Healthcare spending refers to the financial resources allocated to healthcare services, infrastructure, research, and innovations that aim to improve public health. Rising healthcare expenditure is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, and the increasing demand for better healthcare. This rise in healthcare spending helps support the Zorbtive or Serostim market by funding research, improving treatment access, and ensuring insurance coverage for patients with HIV-associated wasting syndrome. For example, in May 2024, the Office for National Statistics in the UK reported that total healthcare expenditure reached approximately $366 billion, reflecting a 5.6% increase from the previous year, with much of this funding coming from government sources. This increase in healthcare spending is expected to continue driving the growth of the Zorbtive or Serostim market.
The key company operating in the zorbtive or serostim market is EMD Serono Inc.
North America was the largest region in the zorbtive or serostim market in 2024. The regions covered in zorbtive or serostim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zorbtive or serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zorbtive and Serostim are both recombinant human growth hormone therapies designed to treat growth hormone deficiency, particularly in patients with conditions such as AIDS-related wasting or severe short stature. These therapies stimulate growth, enhance protein synthesis, and improve overall body composition by increasing lean muscle mass and reducing fat.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Zorbtive and Serostim include short bowel syndrome and HIV-associated wasting. Short bowel syndrome (SBS) is a condition where the body is unable to absorb enough nutrients due to a shortened or compromised small intestine. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by adult and geriatric patients.
The zorbtive or serostim market consists of sales of recombinant human growth hormone products, diagnostic kits, specialty medications, and nutritional and support products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rise in telemedicine platforms, the rise in demand for personalized and targeted treatments, the growth in research and development efforts, the surge in the aging population, and the increase in the prevalence of growth hormone deficiencies. Major trends in the forecast period include a shift towards precision medicine in hormone therapy, the use of home-based injection devices for patient convenience, the popularity of biosimilars as cost-effective alternatives, advancements in drug delivery technologies, and the expansion of market presence in emerging economies.
The rising number of patients with HIV is expected to drive the growth of the Zorbtive or Serostim market in the future. HIV is a virus that weakens the immune system by targeting CD4 cells, which are crucial for defending the body against infections. The increasing prevalence of HIV can be attributed to factors such as unprotected sexual activity, limited access to preventive healthcare, inadequate awareness and education, and difficulties in HIV testing and treatment, especially in high-risk populations. Zorbtive or Serostim addresses HIV-associated wasting syndrome by promoting weight gain, increasing lean body mass, and improving physical function and quality of life for patients with weakened immune systems due to the virus. For example, in April 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 31,800 new HIV infections occurred in the U.S. in 2022, with a significant portion of these cases among gay, bisexual, and other men who reported male-to-male sexual contact. This rising number of HIV patients is contributing to the growth of the Zorbtive or Serostim market.
The increasing focus on personalized treatments is also expected to fuel the growth of the Zorbtive or Serostim market. Personalized medicine tailors therapy to an individual's genetic, environmental, and lifestyle factors to improve treatment outcomes. Advancements in genetic research, better diagnostic tools, and a growing demand for more effective, targeted therapies are driving the rise in personalized treatments. Zorbtive or Serostim fits into this trend by offering a personalized approach to managing HIV-associated wasting syndrome. It helps promote weight gain, increases lean body mass, and enhances physical function, addressing the specific needs of patients with compromised immune systems due to HIV while improving their quality of life. For instance, the Personalized Medicine Coalition reported in February 2023 that personalized medicines accounted for 34% of new drug approvals by the U.S. FDA in 2022 and have consistently made up at least 25% of approvals over the past eight years. This growing emphasis on personalized medicine is likely to drive the Zorbtive or Serostim market.
The overall increase in healthcare spending and investment is expected to further support the growth of the Zorbtive or Serostim market. Healthcare spending refers to the financial resources allocated to healthcare services, infrastructure, research, and innovations that aim to improve public health. Rising healthcare expenditure is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, and the increasing demand for better healthcare. This rise in healthcare spending helps support the Zorbtive or Serostim market by funding research, improving treatment access, and ensuring insurance coverage for patients with HIV-associated wasting syndrome. For example, in May 2024, the Office for National Statistics in the UK reported that total healthcare expenditure reached approximately $366 billion, reflecting a 5.6% increase from the previous year, with much of this funding coming from government sources. This increase in healthcare spending is expected to continue driving the growth of the Zorbtive or Serostim market.
The key company operating in the zorbtive or serostim market is EMD Serono Inc.
North America was the largest region in the zorbtive or serostim market in 2024. The regions covered in zorbtive or serostim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zorbtive or serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zorbtive and Serostim are both recombinant human growth hormone therapies designed to treat growth hormone deficiency, particularly in patients with conditions such as AIDS-related wasting or severe short stature. These therapies stimulate growth, enhance protein synthesis, and improve overall body composition by increasing lean muscle mass and reducing fat.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Zorbtive and Serostim include short bowel syndrome and HIV-associated wasting. Short bowel syndrome (SBS) is a condition where the body is unable to absorb enough nutrients due to a shortened or compromised small intestine. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by adult and geriatric patients.
The zorbtive or serostim market consists of sales of recombinant human growth hormone products, diagnostic kits, specialty medications, and nutritional and support products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Zorbtive Or Serostim Market Characteristics4. Zorbtive Or Serostim Market Trends And Strategies5. Zorbtive Or Serostim Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Zorbtive Or Serostim Pricing Analysis & Forecasts30. Global Zorbtive Or Serostim Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Zorbtive Or Serostim Market32. Recent Developments In The Zorbtive Or Serostim Market
3. Zorbtive Or Serostim Market Biologic Drug Characteristics
6. Global Zorbtive Or Serostim Growth Analysis And Strategic Analysis Framework
8. Zorbtive Or Serostim Market Segmentation
9. Global Zorbtive Or Serostim Epidemiology Of Clinical Indications
10. Zorbtive Or Serostim Market Regional And Country Analysis
11. Asia-Pacific Zorbtive Or Serostim Market
12. China Zorbtive Or Serostim Market
13. India Zorbtive Or Serostim Market
14. Japan Zorbtive Or Serostim Market
15. Australia Zorbtive Or Serostim Market
16. South Korea Zorbtive Or Serostim Market
17. Western Europe Zorbtive Or Serostim Market
18. UK Zorbtive Or Serostim Market
19. Germany Zorbtive Or Serostim Market
20. France Zorbtive Or Serostim Market
21. Eastern Europe Zorbtive Or Serostim Market
22. North America Zorbtive Or Serostim Market
23. USA Zorbtive Or Serostim Market
24. Canada Zorbtive Or Serostim Market
25. South America Zorbtive Or Serostim Market
26. Middle East Zorbtive Or Serostim Market
27. Africa Zorbtive Or Serostim Market
28. Zorbtive Or Serostim Market Competitive Landscape And Company Profiles
29. Global Zorbtive Or Serostim Market Pipeline Analysis
33. Zorbtive Or Serostim Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Zorbtive or serostim Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on zorbtive or serostim market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for zorbtive or serostim ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The zorbtive or serostim market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Short Bowel Syndrome; HIV-Associated Wasting2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult Patients; Geriatric Patients
Key Companies Profiled: EMD Serono Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- EMD Serono Inc.
